Which adverse effect is associated with Amiodarone treatment indicating phospholipidemia?

Which adverse effect is associated with Amiodarone treatment indicating phospholipidemia?

• A. Fatigue
• B. Hypotension
• C. Chest pain
• D. Nausea and vomiting

Answer: (D)

Amiodarone, a potent antiarrhythmic agent, is known for its wide range of potential adverse effects. One significant effect associated with Amiodarone treatment is phospholipidemia, which can manifest as nausea and vomiting. This specific adverse reaction may be linked to the drug's interaction with liver metabolism and its impact on lipid profiles within the body, which can lead to gastrointestinal disturbances. Nausea and vomiting are common issues that arise due to changes in the gastrointestinal system, heightened by the changes in lipid metabolism induced by the drug. While other adverse effects of Amiodarone exist, such as fatigue, hypotension, and chest pain, they do not specifically indicate phospholipidemia. Each of these symptoms can arise from other mechanisms unrelated to lipid metabolism effects specifically caused by Amiodarone. Therefore, the presence of nausea and vomiting serves as a clearer indicator of potential phospholipid-related complications associated with Amiodarone treatment.

Amiodarone, a potent antiarrhythmic agent, is known for its wide range of potential adverse effects. One significant effect associated with Amiodarone treatment is phospholipidemia, which can manifest as nausea and vomiting. This specific adverse reaction may be linked to the drug's interaction with liver metabolism and its impact on lipid profiles within the body, which can lead to gastrointestinal disturbances.

Nausea and vomiting are common issues that arise due to changes in the gastrointestinal system, heightened by the changes in lipid metabolism induced by the drug. While other adverse effects of Amiodarone exist, such as fatigue, hypotension, and chest pain, they do not specifically indicate phospholipidemia. Each of these symptoms can arise from other mechanisms unrelated to lipid metabolism effects specifically caused by Amiodarone. Therefore, the presence of nausea and vomiting serves as a clearer indicator of potential phospholipid-related complications associated with Amiodarone treatment.